Chimeric (ASX:CHM) announces positive FDA feedback after meeting on CHM 2101

March 23, 2023 03:08 PM AEDT | By Ankit Sethi
Follow us on Google News:


  • Chimeric Therapeutics' CHM 2101 has received positive feedback and guidance for proposed Phase 1 clinical trial
  • The advice of the US FDA supports the planned clinical trial of the therapy in gastrointestinal and neuroendocrine tumors
  • The meeting included specific questions on Chimeric's clinical development plan and technical operations

Australia's listed cellular therapy company Chimeric Therapeutics (ASX: CHM) has announced to have received positive and encouraging feedback from the US Food and Drug Administration (FDA) after a pre-Investigational New Drug (pre-IND) meeting for its CAR T cell therapy CHM 2101. Chimeric has stated that this is an important milestone towards an Investigational New Drug Application and clinical trial (Phase 1) of CHM 2101.

Positive US FDA feedback and guidance

The leader in cell therapy in the country has said that the pre-IND meeting has been successfully concluded with the FDA, with the latter giving positive feedback on CHM 2101 development plans. The meeting’s goal was to facilitate regulatory communication and guidance through the Investigational New Drug Application submission process. 

The meeting focused on questions on clinical development and technical operations, which include the drug product manufacturing and quality release for the therapy, Chimeric has stated. 

The US FDA has given encouraging written responses to Chimeric, which according to the latter “validate” its efforts and successes with respect to preparing CHM 2101 for clinic.

Source: CHM ASX announcement dated 21 March 2023

More about CHM 2101

Chimeric states that it is a first in class, third generation autologous CAR T therapy (cellular). The therapy was invented by the University of Pennsylvania, a facility that is a globally renowned cellular therapy centre. CHM 2101’s preclinical evidence has suggested strong evidence of efficacy, CHM has stated. The data demonstrated full eradication of eight types of gastrointestinal cancers, without any incident of relapse or toxicity. The evidence was published in Nature Cancer journal in March last year.

The company is looking toward advancing the cell therapy toward Phase 1A clinical trial for treatment of gastrointestinal and neuroendocrine tumours.

Notably, Chimeric’s CHM 2101 is one of its many cell therapies that include CHM 1101 (CLTX CAR T), which is currently in clinical trial (Phase 1) in recurrent / progressive glioblastoma, and CHM 0201 (CORE-NK platform), which has advanced into Phase 1B clinical trial in blood cancers and solid tumours. Chimeric states that its team of cell therapy experts is targeting discovery, development, and commercialisation of innovative and promising therapies.

CHM shares were trading at AU$0.061 midday on 23 March 2023, up 1.6% from the last close.


The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (Kalkine Media, we or us), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK